OLLI has now printed its June 3 earnings, and the positioning picture that built into that event has largely held — short sellers who rebuilt aggressively through May are sitting on a stock down 7% over the past month and still trading well below where the Street thinks it should be.
Short interest came in at 8.7% of free float as of June 2, nudging above the 8.2% level flagged in last week's pre-earnings note. That's a 30% increase in raw shares over the past month — a sustained rebuild, not a one-week spike. The week-on-week move of 11% confirms shorts added further into the print rather than fading ahead of it. What hasn't changed is the borrow market's indifference to all of this. Cost to borrow is a negligible 0.46%, barely stirring despite the share accumulation. Availability is running at 558% — roughly five and a half shares available for every one already shorted — so the lending pool is nowhere near stressed and there's no structural impediment to positions moving in either direction.
Options traders, who were running notably bullish into the earnings date, have maintained that lean. The put/call ratio is 0.31, below its 20-day average of 0.35 and just off its 52-week low of 0.28. That reading is nearly three-quarters of a standard deviation below the mean — call-side positioning is dominant, and the shift away from the heavy put loading seen back in late April (when PCR touched 0.82) has been sharp and sustained. The ORTEX short score of 51.3 is mid-range and has drifted marginally lower over the past week, consistent with a stock where short conviction is building but not yet at extreme levels.
The biggest structural tension post-earnings is the gap between where OLLI is trading and where analysts think it belongs. The stock closed at $79.25. The mean analyst price target is $129.73 — a 64% implied upside, a gap that is difficult to ignore. The Street has been trimming numbers steadily: Wells Fargo cut its target from $130 to $115 in mid-May, Citigroup moved from $141 to $111 around the same time, and RBC edged its target down from $153 to $152 last week. All three maintained positive ratings. JP Morgan had already trimmed to $152 in April. The direction of travel on price targets is uniformly lower, but every firm still rates the stock positively — a signal that analysts see the discount as an opportunity, not a structural problem. The bull case centres on a +2% annual comp growth target and gross margin expansion toward 40.5%, while bears point to consumer spending headwinds and uncertainty around closeout merchandise supply chains. At 16.8x trailing earnings and 12x EV/EBITDA — both having drifted lower over the past 30 days — the valuation is no longer demanding by historical standards for this name.
One notable institutional development from the most recent filings: Capital Research added 1.36 million shares (now 4.66% of the company), Goldman Sachs Asset Management added 1.64 million shares (3.7%), and a new position from Summit Trail Advisors of 1.58 million shares appeared in the March quarter data. These are material inflows at a time when the stock was trading higher; whether those holders have added further at current levels is the next disclosure to watch.
Closest peer SVV gained 7.2% on the week, a sharp contrast to OLLI's 1.7% decline, suggesting Ollie's underperformed its nearest comparable even as the broader discount retail group recovered. DDS was up 2.8% on the week, adding to the relative underperformance picture.
The next catalyst to track is any post-earnings management commentary on the fiscal outlook — specifically whether the comp growth and margin targets cited in the bull case are reaffirmed or revised, and whether short sellers who built positions into the print now cover or extend their stay.
See the live data behind this article on ORTEX.
Open OLLI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
